Drugs.com - New Drug Approvals

FDA Approves Rapiblyk (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting

Vienna, -- November 27th 2024 -- AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, announced that the U.S. Food and Drug Administration (FDA) has granted regulatory approval for Rapiblyk (landiolol) in the hospital critical...

Feb 9, 2025 - 22:25
 0
FDA Approves Rapiblyk (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting
Vienna, -- November 27th 2024 -- AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, announced that the U.S. Food and Drug Administration (FDA) has granted regulatory approval for Rapiblyk (landiolol) in the hospital critical...
Read More

Tags:

Previous Article

FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar to Stelara

Next Article

FDA Approves Imkeldi (imatinib) Oral Solution for the Treatment of Certain Forms...

Related Posts

FDA Approves Jobevne (bevacizumab-nwgd), a Biosimilar to Avastin

FDA Approves Jobevne (bevacizumab-nwgd), a Biosimilar t...

Apr 15, 2025  0

FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar to Stelara

FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar ...

Feb 9, 2025  0

Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis Announces U.S. FDA Approval of Cabometyx (cabo...

Mar 26, 2025  0